ArticleAnalytical and bioanalytical chemistry2025
StreamFind: data processing workflows for qualification and quantification of biopharmaceutical drug products analyzed by size exclusion chromatography coupled to capillary-enhanced Raman spectroscopy.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Innovative hyphenated technologies, such as size exclusion chromatography coupled with capillary-enhanced Raman spectroscopy (SEC-CERS), enable more comprehensive analyses of biopharmaceutical drug products. However, specialized software for processing and analyzing data from these advanced techniques is often lacking. This study introduces the R package StreamFind, which is designed to help users seamlessly process both chromatographic and Raman spectroscopic data within an integrated workflow. We detail the implementation and structure of StreamFind and demonstrate its ability in the in-depth analysis of biopharmaceutical products. The study shows its capability to differentiate monoclonal antibodies and entire biopharmaceutical formulations and to quantify various components based on their Raman spectra. Principal component analysis (PCA) identified significant differences among the biopharmaceutical products analyzed, while multivariate curve resolution-alternating least squares (MCR-ALS) proved to be an effective method for quantifying different components within these products. The StreamFind platform is designed to be extensible, to facilitate contributions from new users and to support the future integration of additional algorithms to process different types of complex analytical data.
Indexed as
Identifiers
40569409What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.